Inclusion Criteria:

          -  Histologically confirmed R/R B-cell malignancy: DLBCL (THRLBCL, EBV-positive DLBCL of
             the elderly, Grade 3b FL, HGBL with MYC and BCL2 and/or BCL6 rearrangements,
             transformed lymphoma); MCL ((with cyclin D1 overexpression or t(11;14); FL (Grade 1,
             2, 3a); MZL (extranodal, nodal, splenic) ; CLL, or SLL

          -  Willingness to undergo biopsy

          -  At least 2 prior systemic treatment regimens, including prior treatment with an
             anti-CD20 antibody (all cohorts) or prior treatment with a BTK inhibitor (CLL/SLL)

          -  Relapsed, progressive, or refractory NHL or CLL

          -  For NHL/SLL: Radiographically measurable nodal or extranodal disease (all cohorts
             except CLL)

          -  ECOG-PS 0 - 2

          -  LVEF ≥ 50%

          -  Adequate renal, hepatic, bone marrow function

        Exclusion Criteria:

          -  Any other histological type of lymphoma

          -  Primary or secondary CNS lymphoma

          -  Anticancer and/or investigational therapy within the past 30 days or 5 half-lives

          -  Autologous SCT within 6 months of C1D1, and allogeneic SCT within 3 months of C1D1

          -  Previous treatment with CD19-targeted therapy or PI3K inhibitors

          -  Clinically significant cardiac disease

          -  Other malignancy within the past 3 years

          -  Active graft-versus-host disease

          -  Stroke or intracranial hemorrhage within the past 6 months

          -  Chronic or current active infectious disease

          -  Positive virus serology for HCV, HBV, HIV

          -  Currently pregnant or breastfeeding